Seysara costs around $1,100 for a 30-day supply without insurance, compared to roughly $25 for a similar course of generic minocycline. That 40-fold price difference comes down to a few overlapping factors: it’s a brand-name drug with no generic version, it was designed with a narrower antibacterial profile than older acne antibiotics, and the companies behind it spent heavily on development and acquisition before it ever reached pharmacies.
How Seysara’s Price Compares to Alternatives
Without insurance, a 30-day supply of Seysara (60 mg tablets) runs about $36.67 per pill, totaling around $1,100. Generic minocycline 100 mg capsules cost roughly $0.49 per pill, or about $25 for 50 capsules. Generic doxycycline falls in a similar range. Both of those older antibiotics have been available for decades and face heavy generic competition, which keeps their prices low.
Seysara has no generic equivalent. It was approved by the FDA in 2018, and its patent protection means no competing manufacturer can produce a cheaper version yet. That exclusivity is the single biggest driver of the price gap. Every brand-name drug without generic competition carries a steep premium, and Seysara is no exception.
The Cost of Development and Acquisition
Seysara’s journey to market involved multiple companies and significant financial investment. Allergan originally developed the drug, then sold its entire medical dermatology portfolio to the Spanish pharmaceutical company Almirall for $550 million in cash. That deal included Seysara along with several other products, but Almirall made clear that Seysara was the centerpiece, projecting peak annual sales between $150 million and $200 million.
When a company pays that kind of money to acquire a drug, it prices the product to recoup that investment within the window of patent exclusivity. The clinical trial program alone required two large Phase 3 trials and a Phase 2 dose-ranging study, all of which cost tens of millions of dollars to run. Those upfront costs get baked into the price patients see at the pharmacy counter.
What Makes Seysara Different From Older Options
Part of the pricing rationale rests on Seysara being the first narrow-spectrum tetracycline developed specifically for acne. Older antibiotics like doxycycline and minocycline are broad-spectrum, meaning they kill a wide range of bacteria throughout your body, including beneficial ones in your gut. Seysara is 16 to 32 times less active against the normal bacteria living in your intestines compared to those older drugs, and 4 to 8 times less active against common gut anaerobes.
In practical terms, this means Seysara is less likely to cause the digestive side effects that make doxycycline and minocycline hard to tolerate. In clinical trials, diarrhea rates among people taking Seysara were comparable to placebo. Doxycycline, by contrast, is well known for stomach upset and sun sensitivity, while minocycline frequently causes dizziness and vertigo. In Seysara’s trials, vertigo and photosensitivity each occurred in less than 1% of patients.
This narrower approach also carries a theoretical benefit for antibiotic resistance. Because Seysara disrupts fewer bacterial populations in your body, it may cause less overgrowth of resistant bacteria and fewer secondary infections like yeast infections. The acne-causing bacteria themselves showed a low tendency to develop resistance to Seysara in lab testing, with mutation rates similar to those seen with minocycline and vancomycin (two drugs known for low resistance development).
Does It Work Better Than Cheaper Antibiotics?
Seysara’s clinical results are solid but not dramatically superior to what older tetracyclines achieve. In its two Phase 3 trials, Seysara reduced inflammatory acne lesions by about 50 to 52% over 12 weeks, compared to 35% with placebo. That’s a statistically significant difference, and improvement started as early as week 3. However, doxycycline and minocycline produce similar reductions in inflammatory lesions in their own trials.
The real clinical advantage isn’t greater acne clearance. It’s the side effect profile. If you’ve tried doxycycline and couldn’t tolerate the nausea or sun sensitivity, or minocycline gave you dizziness, Seysara offers a genuinely easier experience for many people. The once-daily dosing is also simpler than some minocycline regimens. Whether that tolerability advantage is worth the price difference depends entirely on your situation and insurance coverage.
Ways to Lower the Cost
Most people paying $1,100 out of pocket for Seysara aren’t getting the best available price. Almirall offers a manufacturer savings card that can bring copays down significantly for people with commercial insurance, sometimes to as little as $0 to $25 per month. Without commercial insurance, those programs typically don’t apply.
If your insurance covers Seysara but requires prior authorization, your dermatologist can submit documentation showing you’ve tried and failed cheaper alternatives. Many insurers require this “step therapy” before approving a brand-name antibiotic. If your plan denies coverage entirely, or if you’re uninsured, it’s worth asking your dermatologist whether generic doxycycline or minocycline at a fraction of the cost would be a reasonable starting point. For many patients with moderate to severe acne, the older drugs work just as well, and the price difference is hard to justify unless tolerability is a real problem.